Role of Myosin II in Ischemic Acute Renal Failure

Project: Research project

Description

DESCRIPTION (provided by applicant) The overall mortality rate for patients with acute renal failure (ARF) has remained 40-50% for the past 30 years. The associated annual cost of ARF is over $12 billion. Ischemia is the leading cause of ARF and alterations in the actin cytoskeleton of renal tubular cells during ischemia and recovery have important consequences for kidney function. The long-term goal of this project is to understand how myosin Il (MII) and the Rho GTPases interact to regulate protective and reparative alterations in the actin cytoskeleton of renal tubular cells during ischemia and recovery. The general strategy is to study ATP depletion as a reversible cell culture model of ischemia that has been shown to recapitulate alterations in the actin cytoskeleton observed from in vivo studies of ischemia. Mutant proteins will be used as molecular probes to conduct studies not possible in animals or humans. The proposed experiments will test the hypothesis that MII is an important distal effector of the Rho regulatory cascade and plays a critical role in regulating the actin cytoskeleton in renal tubular cells during ischemia and recovery. Grant funding and extended training in cell biology is a major factor in the PI's immediate goal of attaining research independence and the long-term career goal of becoming a successful and productive investigator in an academic institute. The specific aims of this present study are as follows: 1) Determine the effects of altering MII activation on the actin cytoskeleton and cell adhesion during cellular ATP depletion and recovery. Mutant forms of myosin Iight chain kinase (MLCK) will be expressed in MDCK cells to alter the activation state of myosin II. In all specific aims, immunofluorescence confocal microscopy will be utilized to examine actin and MII distribution as well as structures important for cell-matrix adhesion. Standard assays will be used to examine MII activation and cell adhesion. 2) Determine the effects on the actin cytoskeleton of altering MII activation while inversely altering Rho signaling during cellular ATP depletion and recovery. Mutant forms of MLCK and Rho proteins will be co-expressed in MDCK cells to alter cellular signaling. 3) Determine the effects on the actin cytoskeleton of altering Rho-kinase (ROCK) signaling while inversely altering Rho signaling during cellular ATP depletion and recovery. Mutant forms of ROCK and Rho proteins will be co-expressed in MDCK cells to alter cellular signaling. 4) Determine the effects on the actin cytoskeleton of altering MII activation while inversely altering ROCK signaling during cellular ATP depletion and recovery. Mutant forms of MLCK and ROCK proteins will be co-expressed in MDCK cells to alter cellular signaling.
StatusFinished
Effective start/end date4/15/0211/30/07

Funding

  • National Institutes of Health: $125,018.00
  • National Institutes of Health: $125,676.00
  • National Institutes of Health: $124,378.00
  • National Institutes of Health: $123,140.00
  • National Institutes of Health: $123,759.00

Fingerprint

Myosin Type II
Myosins
Actin Cytoskeleton
Acute Kidney Injury
Madin Darby Canine Kidney Cells
Ischemia
Adenosine Triphosphate
Kidney
Cell Adhesion
Cell-Matrix Junctions
Molecular Probes
rho-Associated Kinases
rho GTP-Binding Proteins
Proteins
Mutant Proteins
Fluorescence Microscopy
Confocal Microscopy
Cell Biology
Actins
Phosphotransferases

ASJC

  • Medicine(all)